During checkout, this product may be reported as "Out of Stock" with an Estimated Availability date. The Actual Availability date for this product may be earlier. Send inquiries regarding Actual Availability date, including the catalog number, to discoverysciences@lifetech.com.

CellSensor® AP-1-bla A375 Cell Line

Catalog number: K1660

 Related applications: Pharma & Biopharma | Target & Lead Identification & Validation

Error loading your content!

  Catalog number
Select a plan
Unit size
Price ({{currency}}) Your price ({{currency}}) Availability Qty
{{product.sku}} {{product.sku}}
also known as {{product.formattedSku}} 
{{subscriptionDetails.selectedRatePlan.billingPeriod}} {{subscriptionDetails.selectedRatePlan.billingPeriod}} {{product.availability.message}}
Pro add-ons

Your on-site stock

›› {{supplyCenter.scName}}({{scProduct.stockOnHand}} In stock)
›› {{supplyCenter.scName}}(Out of stock)
›› {{supplyCenter.scName}}
This item is not currently available on-site. Depending on your Supply Center settings you may be able to add the item to cart above else use the Order Non-Stocked Items' tab on the Supply Center home page.
Back to top


The CellSensor® AP1-bla A375 cell line contains a beta-lactamase reporter gene under control of the AP1 response element stably integrated into A375 cells. A375 cells are human melanoma cancer cells that contain the endogenous B-Raf mutation V600E resulting in constitutive B-Raf kinase activity. The CellSensor® AP1-bla A375 cell line is a clonal population isolated by flow cytometry based on constitutive expression of beta-lactamase. This cell line has been validated with various small-molecule Raf inhibitors as well as B-Raf Stealth RNAi™ siRNA. This cell line has also been tested for assay performance under variable conditions, including DMSO concentration, cell number, compound incubation time, and substrate loading time and validated for Zfi-factor and IC50 concentrations of Raf1 Inhibitor I. The RAF gene family (RAF1, A-RAF, and B-RAF) encodes closely related serine/threonine protein kinases that are important effectors of Ras activation. Raf1 and A-Raf are rarely mutated, whereas mutations in B-Raf are common in human cancers, especially melanoma. B-Raf is mutated in about 70% of human melanomas, 35-70% of papillary thyroid carcinomas, and less commonly in lung and colorectal carcinomas. Mutations are mostly in the B-Raf kinase domain and, in melanomas, the vast majority are V600E missense mutations leading to activation of B-Raf kinase. The constitutive activity of B-Raf V600E can directly lead to the activation of the Mek/MAPK signaling pathway. Therefore, inhibition of B-Raf/Mek/MAPK signaling could be a potential way of treating melanomas and other tumors with mutant B-Raf.
For Research Use Only. Not for use in diagnostic procedures.


System: CellSensor™
Cell State: Dividing Cells
Product Size: 1 vial
Druggable Target: Signaling Pathway

Contents & storage

CellSensor® Cell Lines are shipped on dry ice. Store in liquid nitrogen immediately upon receipt, or thaw for immediate use.


Manuals & protocols